Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

In the current era of precision medicine, the identification of genomic alterations has
revolutionised the management of patients with solid tumours. Recent advances in the …

Highlights•Cell-free nucleic acids in body fluids contain tumour fragments that can be
profiled for prognostic and diagnostic information for the management of cancer.•cfDNA …

Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects the
heterogeneity of primary cancers and their metastases. As a noninvasive, real-time …

The recent understanding of tumour heterogeneity and cancer evolution in response to
therapy has raised questions about the value of historical or single site biopsies for guiding …

Circulating tumor DNA (ctDNA) is now being extensively studied as it is a noninvasive “real-
time” biomarker that can provide diagnostic and prognostic information before, during …

Circulating cell-free tumor DNA (ctDNA) is a promising biomarker in cancer. Ultrasensitive
technologies enable detection of low (< 0.1%) mutant allele frequencies, a pre-requisite to …

Cell-free DNA (cfDNA) refers to short fragments of acellular nucleic acids detectable in
almost all body fluids, including blood, and is involved in various physiological and …

Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

Background Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for
cancer screening, monitoring relapse/recurrence and evaluating response to treatment …